Literature DB >> 1109767

Inhibitory effect of prolonged Corynebacterium parvum and cyclophosphamide administration on the growth of established tumors.

B Fisher, N Wolmark, E Saffer, E R Fisher.   

Abstract

The present study was carried out to investigate the effects of prolonged administration of C. parvum alone and in combination with cyclophosphamide for the treatment of established, measurable C3H tumors. The continued weekly administration of C. parvum by itself provided a limited but significant inhibitory effect on tumor growth and significantly prolonged survival. Intraperitoneal and intravenous administration was found to be more effective than the subcutaneous route. When C. parvum was administered asynchronously in combination with cyclophosphamide at weekly intervals a tumor growth inhibitory effect was achieved which was greater than that resulting from either agent along. Such an effect was consistently obtained and was seemingly independent of the sequence of drug administration. When cyclophosphamide preceded the initial C. parvum administration, arrest in the rate of tumor growth occurred, resulting in infinite tumor doubling time for the duration of observation (greater than 90 days). The combination of C. parvum and cyclophosphamide produced a more effective inhibition of tumor growth than did BCG and cyclophosphamide similarly employed. The importance of these findings relative to clinical application is considered. While the significance and genesis of the marked desmoplastic reaction characterizing tumors from animals treated with C. parvum and cyclophosphamide is at present speculative, consideration is given to the possibility that this could signify a host response against tumor growth.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1109767     DOI: 10.1002/1097-0142(197501)35:1<134::aid-cncr2820350119>3.0.co;2-g

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

Review 1.  Salmonella-allies in the fight against cancer.

Authors:  Sara Leschner; Siegfried Weiss
Journal:  J Mol Med (Berl)       Date:  2010-06-05       Impact factor: 4.599

2.  Immune adjuvants for chemotherapy or radiotherapy in the 9L rat brain tumor model.

Authors:  C Liu; B F Kimler; R G Evans; R A Morantz
Journal:  J Neurooncol       Date:  1993-02       Impact factor: 4.130

3.  Personal experience with Corynebacterium parvum in human cancers.

Authors:  L Israël; R Edelstein
Journal:  World J Surg       Date:  1977-09       Impact factor: 3.352

4.  A study of reactions to Corynebacterium parvum (C. parvum) in the brain and dermis of the rat.

Authors:  H M Cravioto; G M Hochwald; J Ransohoff
Journal:  Acta Neuropathol       Date:  1982       Impact factor: 17.088

5.  Effects of Corynebacterium parvum treatment and Toxoplasma gondii infection on macrophage-mediated cytostasis of tumour target cells.

Authors:  J L Krahenbuhl; L H Lambert; J S Remington
Journal:  Immunology       Date:  1976-12       Impact factor: 7.397

6.  Antitumour effect of corynebacterium parvum. Possible mode of action.

Authors:  M Baum; M Breese
Journal:  Br J Cancer       Date:  1976-04       Impact factor: 7.640

7.  Harmful effects of i.v. Corynebacterium Parvum given at the same time as cyclophosphamide in patients with squamous-cell carcinoma of the bronchus.

Authors:  B M von Blomberg; J Glerum; J J Croles; J Stam; H A Drexhage
Journal:  Br J Cancer       Date:  1980-04       Impact factor: 7.640

8.  Single versus multiple human-equivalent doses of C. parvum in mice: neutralization of the anti-metastatic effect.

Authors:  H D Mitcheson; T E Sadler; J E Castro
Journal:  Br J Cancer       Date:  1980-03       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.